amfAR, The Foundation for AIDS Research

amfAR-Funded Cure Research

Principal Investigators and Key Personnel

In just the first 24 months of amfAR’s Countdown to a Cure for AIDS initiative, we have supported 139 principal investigators and key personnel in 16 U.S. states and 9 other countries around the world.

Adam Abate
University of California, San Francisco, San Francisco, CA

Cell-Intrinsic Immune Modulation of HIV Latency 109111

Luis Agosto
Boston Medical Center, Boston, MA

HIV Cell-to-Cell Transmission and the Establishment of Latency 109263

Galit Alter
Ragon Institute of MGH, MIT and Harvard, Boston, MA

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Michael Axthelm
Oregon Health & Science University, Portland, OR

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

amfAR Institute for HIV Cure Research 109301

Peter Bacchetti
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Dan Barouch
Beth Israel Deaconess Medical Center, Boston, MA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Greg Barton
University of California, Berkeley, Berkeley, CA

amfAR Institute for HIV Cure Research 109301

Scott Bateman
Celgene, San Diego, CA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Nadejda Beliakova-Bethell
University of California, San Diego, La Jolla, CA

Genomic locations of HIV proviruses responsive to latency reversing agents 109339

Julià Blanco
AIDS Research Institute IrsiCaixa, Barcelona, SPAIN

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Karol Bomsztyk
University of Washington, Seattle, WA

Epigenetic mechanisms of HIV transcriptional activation 109099

Dennis Burton
The Scripps Research Institute, La Jolla, CA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Benjamin Burwitz
Oregon Health & Science University, Portland, OR

Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques 109100

Michael Busch
Blood Systems Research Institute, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Cheryl Cameron
Case Western Reserve University, Cleveland, OH

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

Paul Cameron
The University of Melbourne, Melbourne, AUSTRALIA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Darrick Carter
Infectious Disease Research Institute, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Ann Chahroudi
Emory University, Atlanta, GA

Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART 109353

Nicolas Chomont
Université de Montréal, Montreal, CANADA

The size and maintenance of the latent HIV reservoir in T-cell subsets 109316

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Uncovering HIV-1-infected cells: a new path towards a cure 109343

Kiera Clayton
Ragon Institute of MGH, MIT and Harvard, Boston, MA

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Biswajit Das
Case Western Reserve University School of Medicine, Cleveland, OH

Hormonal control of latent HIV proviruses 109347

Steven Deeks
University of California, San Francisco, San Francisco, CA

Predictors of time to viremia with an analytic treatment interruption 109496

Cell-Intrinsic Immune Modulation of HIV Latency 109111

Impact of everolimus on HIV persistence post kidney or liver transplant 109119

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

amfAR Institute for HIV Cure Research 109301

Analytic Treatment Interruption to Study Viral Reservoirs and as Test for Cure in HIV-infected Adults on ART 109380

Xuato Deng
Blood Systems Research Institute, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Jun Deng
Monash University, Melbourne, AUSTRALIA

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Oleg Denisenko
University of Washington, Seattle, WA

Epigenetic mechanisms of HIV transcriptional activation 109099

Paul Denton
Aarhus University Hospital, Aarhus, DENMARK

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs 109328

Jose Luis Diez Martin
Hospital General Universitario Gregorio Marañón, Barcelona, SPAIN

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Curtis Dobrowolski
Case Western Reserve University School of Medicine, Cleveland, OH

Quantitative HIV reservoir assay using bar-coded RNA 109348

Hormonal control of latent HIV proviruses 109347

Christine Durand
Johns Hopkins University, Baltimore, MD

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Mohamed El-Far
Université de Montréal, Montréal, CANADA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Jacob Estes
Leidos Biomedical Research, Frederick, MD

Interleukin-21 therapy to reduce HIV persistence 109109

Vanessa Evans
The University of Melbourne, Melbourne, AUSTRALIA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Gerd Fatkenheuer
University Hospital of Cologne, Cologne, GERMANY

Combining romidepsin and 3BNC117 to deplete the HIV-1 reservoir 109144

Andres Finzi
CRCHUM / Université de Montréal, Montreal, CANADA

Uncovering HIV-1-infected cells: a new path towards a cure 109343

Richard Flavell
Yale University, New Haven, CT

Identification, reactivation and elimination of latent HIV-1 in humanized mice 109277

Benjamin Franc
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Lisa Frenkel
University of Washington, Seattle, WA

Epigenetic mechanisms of HIV transcriptional activation 109099

Remi Fromentin
Université de Montréal, Montréal, CANADA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Julia Garcia Prado
AIDS Research Institute IrsiCaixa, Barcelona, SPAIN

Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir 109382

Romas Geleziunas
Gilead Sciences, San Francisco, CA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Paul Gorry
Burnet Institute, Melbourne, AUSTRALIA

Understanding the role of the HIV Envelope in viral persistence and latency 109114

Warner Greene
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Erik Hansen
Johns Hopkins University, Baltimore, MD

Discovery of Tools to Modify the Fate of Uracilated HIV DNA in Macrophages 109361

Hobart Harris
University of California, San Francisco, San Francisco, CA

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

Hiroyu Hatano
University of California San Fransisco, San Fransisco, CA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

Frederick Hecht
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Andrew Henderson
Boston Medical Center, Boston, MA

HIV Cell-to-Cell Transmission and the Establishment of Latency 109263

Jon Hennebold
Oregon Health & Science University, Portland, OR

Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques 109100

Timothy Henrich
University of California, San Francisco, San Francisco, CA

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART 109353

amfAR Institute for HIV Cure Research 109301

John Heyman
Harvard University, Boston, MA

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Priscilla Hsue
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Peter Hunt
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Gero Hütter
Cellex, Dresden, GERMANY

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Nuria Izquierdo-Useros
AIDS Research Institute IrsiCaixa, Barcelona, SPAIN

Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir 109382

Brad Jones
The George Washington University, Washington DC, DC

Combining CTL with TLR-2 Agonists to Eradicate Natural HIV Reservoirs 109315

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Boris Juelg
Ragon Institute of MGH, MIT, and Harvard, Boston, MA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Jonathan Karn
Case Western Reserve University School of Medicine, Cleveland, OH

Hormonal control of latent HIV proviruses 109347

Quantitative HIV reservoir assay using bar-coded RNA 109348

Sheila Keating
Blood Systems Research Institute, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Jurgen Kuball
University Medical Center Utrecht, utrecht, NETHERLANDS

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Priti Kumar
Yale University, New Haven, CT

Identification, reactivation and elimination of latent HIV-1 in humanized mice 109277

Alan Landay
Rush University Medical Center, Chicago, IL

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Lewis Lanier
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Zoltan Laszik
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Sulggi Lee
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Sharon Lewin
Peter Doherty Institute, Melbourne, AUSTRALIA

Understanding the role of the HIV Envelope in viral persistence and latency 109114

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Mark Lewis
Bioqual, Rockville, MD

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Qingsheng Li
Board of Regents, Univ of Nebraska, Univ of Nebraska-Lincoln, Lincoln, NE

CNS as Reservoir for Subtype C HIV-1 Infection 109123

Mathias Lichterfeld
Ragon Institute of MGH, MIT and Harvard, Boston, MA

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Teri Liegler
University of California, San Francisco, San Francisco, CA

Impact of everolimus on HIV persistence post kidney or liver transplant 109119

amfAR Institute for HIV Cure Research 109301

Jeffrey Lifson
Frederick National Laboratory for Cancer Research, Frederick, MD

Interleukin-21 therapy to reduce HIV persistence 109109  

Maier Lorizate
University of the Basque Country, Barcelona, SPAIN

Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir 109382

Jeffrey Martin
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Javier Martinez-Picado
AIDS Research Institute IrsiCaixa, Barcelona, SPAIN

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir 109382

Marta Massanella
Université de Montréal, Montreal, CANADA

The size and maintenance of the latent HIV reservoir in T-cell subsets 109316

Maud Mavigner
Emory University, Atlanta, GA

Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART 109353

Richard Maziarz
Oregon Health & Science University, Portland, OR

Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques 109100

Mike McCune
University of California, San Francisco, San Francisco, CA

Predictors of time to viremia with an analytic treatment interruption 109496

amfAR Institute for HIV Cure Research 109301

Luca Micci
Emory University, Atlanta, GA

Interleukin-21 therapy to reduce HIV persistence 109109  

Jeffrey Milush
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

James Mullins
University of Washington, Seattle, WA

Epigenetic mechanisms of HIV transcriptional activation 109099

Quantitative HIV reservoir assay using bar-coded RNA 109348

Jan Münch
Ulm University, Ulm, GERMANY

Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs 109328

Monique Nijhuis
University Medical Center Utrecht, Utrecht, NETHERLANDS

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals (renewal) 109293

Michel Nussenzweig
The Rockefeller University, New York, NY

Combining romidepsin and 3BNC117 to deplete the HIV-1 reservoir 109144

Afam Okoye
Oregon Health Sciences University, Portland, OR

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

amfAR Institute for HIV Cure Research 109301

Lars Østergaard
Aarhus University Hospital, Aarhus, DENMARK

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Melanie Ott
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Mirko Paiardini
Emory University, Atlanta, GA

Interleukin-21 therapy to reduce HIV persistence 109109

Mechanisms and correlates of post-ART treatment control in SIV-infected macaques 109354

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Peilin Li
San Francisco VA Medical Center, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Boris Matija Peterlin
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Louis Picker
Oregon Health and Science University, Portland, OR

amfAR Institute for HIV Cure Research 109301

Satish Pillai
Blood Systems Research Institute, San Francisco, CA

Cell-Intrinsic Immune Modulation of HIV Latency 109111

amfAR Institute for HIV Cure Research 109301

Vicente Planelles
University of Utah, Salt Lake City, UT

Molecular characterization of non-induced proviruses 109112

David Price
University of Iowa, Iowa City, IA

Molecular characterization of non-induced proviruses 109112

Miguel Quinones-Mateu
Case Western Reserve University School of Medicine, Cleveland, OH

Quantitative HIV reservoir assay using bar-coded RNA 109348

Thomas Rasmuusen
Aarhus University Hospital, Aarhus, DENMARK

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Steve Reed
Infectious Disease Research Institute, Seattle, WA

amfAR Institute for HIV Cure Research 109301

Douglas Richman
University of California San Diego, La Jolla, CA

The size and maintenance of the latent HIV reservoir in T-cell subsets

Nadia Roan
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Remy Robert
Monash University, Melbourne, AUSTRALIA

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Harriet Latham Robinson
GeoVax, Atlanta, GA

amfAR Institute for HIV Cure Research 109301

Vanderson Rocha
Churchill Hospital, Oxford University, Headington, UK

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Michael Roche
Peter Doherty Institute, Melbourne, AUSTRALIA

Understanding the role of the HIV Envelope in viral persistence and latency 109114

Rodney Rogers
University of California, San Francisco, San Francisco, CA

Impact of everolimus on HIV persistence post kidney or liver transplant 109119

Jonah Sacha
Oregon Health & Science University, portland, OR

Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques 109100

Asier Saez-Cirion
Institut Pasteur, Paris, FRANCE

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Maria Salgado
AIDS Research Institute IrsiCaixa, Barcelona, SPAIN

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Shomyseh Sanjabi
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Timothy Schacker
University of Minnesota, Minneapolis, MN

Predictors of time to viremia with an analytic treatment interruption 109496

Julian Schulze zur Wiesch
University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

Kyle Seamon
Johns Hopkins University, Baltimore, MD

Discovery of Tools to Modify the Fate of Uracilated HIV DNA in Macrophages 109361

Rafick-Pierre Sekaly
Case Western Reserve University, Cleveland, OH

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

Liang Shan
Yale University, New Haven, CT

Identification, reactivation and elimination of latent HIV-1 in humanized mice 109277

Amos Smith III
University of Pennsylvania, Philadelphia, PA

Uncovering HIV-1-infected cells: a new path towards a cure 109343

Joseph Sodroski
Dana-Farber Cancer Institute / Harvard medical school, Boston, MA

Uncovering HIV-1-infected cells: a new path towards a cure 109343

Ole Sogaard
Aarhus University Hospital - Skejby, Aarhus, DENMARK

Combining romidepsin and 3BNC117 to deplete the HIV-1 reservoir 109144

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Celsa Spina
University of California, San Diego, La Jolla, CA

Genomic locations of HIV proviruses responsive to latency reversing agents 109339

Kathryn Stephenson
Beth Israel Deaconess Medical Center, Boston, MA

Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication 109219

Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function 109222

James Stivers
Johns Hopkins University, Baltimore, MD

Discovery of Tools to Modify the Fate of Uracilated HIV DNA in Macrophages 109361

Peter Stock
University of California, San Francisco, San Francisco, CA

Impact of everolimus on HIV persistence post kidney or liver transplant 109119

Matthew Strain
University of California San Diego, La Jolla, CA

The size and maintenance of the latent HIV reservoir in T-cell subsets 109316

Andrew Tager
Ragon Institute of MGH, MIT and Harvard, Boston, MA

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Ahmed Tawakol
Massachusetts General Hospital, Boston, MA

amfAR Institute for HIV Cure Research 109301

Martin Tolstrup
Aarhus University Hospital, Aarhus, DENMARK

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs 109328

amfAR Institute for HIV Cure Research 109301

Henry VanBrocklin
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Linos Vandekerckhove
Ghent University, Ghent, BELGIUM

Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy 109118

Eric Verdin
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Paul Volberding
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Bruce Walker
Ragon Institute of MGH, MIT and Harvard, Boston, MA

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Leor Weinberger
The J. David Gladstone Institutes, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

David Weitz
Harvard University, Boston, MA

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells 109326

Annemarie Wensing
University Medical Center Utrecht, Utrecht, NETHERLANDS

Allogeneic Stem Cell Transplant in HIV-1-Infected Individuals 109293

John West
Board of Regents, Univ of Nebraska, Univ of Nebraska-Lincoln, Lincoln, NE

CNS as Reservoir for Subtype C HIV-1 Infection 109123

Fiona Wightman
The University of Melbourne, Melbourne, AUSTRALIA

Combination immune checkpoint blocker inhibition to eliminate HIV latency 109226

Paul Wille
Case Western Reserve University School of Medicine, Cleveland, OH

Hormonal control of latent HIV proviruses 109347

Joseph Wong
San Francisco VA Medical Center, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Charles Wood
Board of Regents, Univ of Nebraska, Univ of Nebraska-Lincoln, Lincoln, NE

CNS as Reservoir for Subtype C HIV-1 Infection 109123

Di Yu
Monash University, Melbourne, AUSTRALIA

Development of a humanized superagonist antibody to human IL-21 for HIV cure 109327

Steven Yukl
University of California, San Francisco, San Francisco, CA

amfAR Institute for HIV Cure Research 109301

Alexander Zelikin
Aarhus University, Aarhus, DENMARK

Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs 109328